Find out more about Robin Filshie's experience
Robin Filshie's highlights
Robin Filshie's selected work
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of resi..
Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Pa..
Thrombotic microangiopathy associated with intravenous injection of extended-release oxyco..
Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Ste..
Results of a phase II study of thalidomide and azacitidine in patients with clinically adv..
Displaying the 20 most recent scholarly works by Robin Filshie.
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, David M Ross, Susan Branford, Jason Butler, Robin Filshie, Henry Januszewicz, David Joske, Anthony Mills, David Simpson, Constantine Tam, Kerry Taylor, Anne-Marie Watson, Max Wolf, Andrew Grigg
Journal article | 2019 | Leukemia & Lymphoma
The management of CML in pregnancy is challenging with the need to balance disease control against potential teratogenic effects o..
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Dang Phuong, Verity A Saunders, Jodi Braley, Agnes S Yong, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes
Journal article | 2018 | Leukemia
Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Dang Phuong, Verity A Saunders, Jody Braley, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes
Conference Proceedings | 2017 | BLOOD
Thrombotic microangiopathy associated with intravenous injection of extended-release oxycodone.
Kate J Robson, Danielle Clucas, Robin Filshie, Harshal Nandurkar
Journal article | 2017 | BMJ Case Reports
We describe the case of a 35-year-old man presenting with thrombotic microangiopathy (TMA) and renal impairment following, as he l..
Early Treatment Intensification With R-ICE And 90Y-Ibritumomab Tiuxetan (Zevalin)-BEAM Stem Cell Transplantation In Patients With High Risk Diffuse Large B-Cell Lymphoma Patients And Positive Interim PET After 4 Cycles Of R-CHOP-14
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, et al.
Journal article | 2017 | Haematologica
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)
Melita Kenealy, Nigel Patton, Robin Filshie, Andrew Nicol, Shir-Jing Ho, Mark Hertzberg, Tony Mills, Ian Prosser, Emma Link, Linda Cowan, Diana Zannino, John F Seymour
Journal article | 2017 | Leukemia & Lymphoma
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial
Harry J Iland, Marnie Collins, Ken Bradstock, Shane G Supple, Alberto Catalano, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Lynda J Campbell, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, et al.
Journal article | 2015 | The Lancet Haematology
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
David T Yeung, Michael P Osborn, Deborah L White, Susan Branford, Jodi Braley, Alan Herschtal, Michael Kornhauser, Samar Issa, Devendra K Hiwase, Mark Hertzberg, Anthony P Schwarer, Robin Filshie, Christopher K Arthur, Yiu Lam Kwan, Judith Trotman, Cecily J Forsyth, John Taper, David M Ross, Jennifer Beresford, Constantine Tam, et al.
Journal article | 2015 | Blood
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M Ross, Susan Branford, John F Seymour, Anthony P Schwarer, Christopher Arthur, David T Yeung, Dang Phuong, Jarrad M Goyne, Cassandra Slader, Robin J Filshie, Anthony K Mills, Junia V Melo, Deborah L White, Andrew P Grigg, Timothy P Hughes
Journal article | 2013 | Blood
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)
Harry J Iland, Ken Bradstock, Shane G Supple, Alberto Catalano, Marnie Collins, Mark Hertzberg, Peter Browett, Andrew Grigg, Frank Firkin, Amanda Hugman, John Reynolds, Juliana Di Iulio, Campbell Tiley, Kerry Taylor, Robin Filshie, Michael Seldon, John Taper, Jeff Szer, John Moore, John Bashford, et al.
Journal article | 2012 | Blood
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR
DM Ross, S Branford, JF Seymour, AP Schwarer, C Arthur, PA Bartley, C Slader, C Field, P Dang, RJ Filshie, AK Mills, AP Grigg, JV Melo, TP Hughes
Journal article | 2010 | Leukemia
Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy
Timothy P Hughes, Susan Branford, Deborah L White, John Reynolds, Rachel Koelmeyer, John F Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K Mills, Keith Fay, Simon Durrant, Henry Januszewicz, et al.
Journal article | 2008 | Blood
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia
Deborah White, Verity Saunders, Andrew Grigg, Chris Arthur, Robin Filshie, Michael F Leahy, Kevin Lynch, L Bik To, Timothy Hughes
Journal article | 2007 | Journal of Clinical Oncology
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha
Susan Branford, Timothy Hughes, Alvin Milner, Rachel Koelmeyer, Anthony Schwarer, Chris Arthur, Robin Filshie, Susan Moreton, Kevin Lynch, Kerry Taylor
Journal article | 2007 | Cancer
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations
S Branford, Z Rudzki, I Parkinson, A Grigg, K Taylor, JF Seymour, S Durrant, P Browett, AP Schwarer, C Arthur, J Catalano, MF Leahy, R Filshie, K Bradstock, R Herrmann, D Joske, K Lynch, T Hughes
Journal article | 2004 | Blood
Protective effects of recombinant human antithrombin III in pig-to-primate renal xenotransplantation
PJ Cowan, A Aminian, H Barlow, AA Brown, K Dwyer, RJA Filshie, N Fisicaro, DMA Francis, H Gock, DJ Goodman, J Katsoulis, SC Robson, E Salvaris, TA Shinkel, AB Stewart, AJF d'Apice
Journal article | 2002 | American Journal of Transplantation
Medicine - St Vincent'S Hospital